glp-1 for nash Resmetirom and agonists MASH: complementary rather than exclusive GLP-1 Receptor Agonists as Treatments

While Lilly and Novo dominate today's $50B+ obesity market, Pfizer is preparing a killer portfolio to steal the spotlight in 2030s

The study, which has not yet undergone peer review, included 751 people with obesity, or those who were overweight with a related medical condition

Brand-name semaglutide (Wegovy) carries a list price of approximately $1,300 to $1,500 per month

The complex interplay between metabolism, inflammation, and brain health suggests GLP-1 receptor agonists could become powerful tools against cognitive decline and promote healthier aging

While ertugliflozin did not outperform placebo for MACE, it significantly reduced hospitalizations for HF by 30% ( The SCORED clinical study, which included 10,584 patients with T2DM and an estimated glomerular filtration rate (eGFR) of 2560 ml/m/1.73 m, evaluated the effects of sotagliflozin on cardiovascular death and hospitalization for HF